# Title
Comparison O
of O
cytochrome O
P-450-dependent O
metabolism O
and O
drug O
interactions O
of O
the O
3-hydroxy-3-methylglutaryl-CoA B-Gene
reductase I-Gene
inhibitors O
lovastatin B-Chemical
and O
pravastatin B-Chemical
in O
the O
liver. O

# Abstract
In O
an O
in O
vitro O
study, O
the O
cytochrome B-Gene
P-450 I-Gene
3A I-Gene
(CYP3A)-dependent O
metabolism O
and O
drug O
interactions O
of O
the O
3-hydroxy-3-methylglutaryl-Co B-Gene
A I-Gene
reductase I-Gene
inhibitors O
lovastatin B-Chemical
and O
pravastatin B-Chemical
were O
compared. O
Lovastatin B-Chemical
was O
metabolized O
by O
human B-Species
liver O
microsomes O
to O
two O
major O
metabolites: O
6'beta-hydroxy B-Chemical
[Michaelis-Menten O
constant O
(Km): O
7.8 O
+ O
- O
2.7 O
microM] O
and O
6'-exomethylene B-Chemical
lovastatin B-Chemical
(Km,10.3 O
+ O
- O
2.6 O
microM). O
6'beta-Hydroxylovastatin B-Chemical
formation O
in O
the O
liver O
was O
inhibited O
by O
the O
specific O
CYP3A B-Gene
inhibitors O
cyclosporine B-Chemical
(Ki, O
7.6 O
+ O
- O
2.3 O
microM), O
ketoconazole B-Chemical
(Ki, O
0.25 O
+ O
- O
0.2 O
microM), O
and O
troleandomycin B-Chemical
(Ki, O
26.6 O
+ O
- O
18.5 O
microM). O
Incubation O
of O
pravastatin B-Chemical
with O
human B-Species
liver O
microsomes O
resulted O
in O
the O
generation O
of O
3'alpha,5'beta, B-Chemical
6'beta-trihydroxy I-Chemical
pravastatin B-Chemical
(Km, O
4,887 O
+ O
- O
2,185 O
microM) O
and O
hydroxy O
pravastatin B-Chemical
(Km, O
20,987 O
+ O
- O
9,389 O
microM). O
The O
formation O
rates O
of O
3'alpha,5'beta,6'beta-trihydroxy B-Chemical
pravastatin B-Chemical
by O
reconstituted O
CYP3A B-Gene
enzymes O
were O
(1,000 O
microM O
pravastatin) B-Chemical
1.9 O
+ O
- O
0.6 O
pmol.min-1.pmol O
CYP3A4 B-Gene
and O
0.06 O
+ O
- O
0.04 O
pmol.min-1.pmol O
CYP3A5, B-Gene
and O
the O
formation O
rates O
of O
hydroxy O
pravastatin B-Chemical
were O
0.12 O
+ O
- O
0.02 O
pmol.min-1.pmol O
CYP3A4 B-Gene
and O
0.02 O
+ O
- O
0.004 O
pmol.min-1.pmol O
CYP3A5. B-Gene
The O
specific O
CYP3A B-Gene
inhibitors O
cyclosporine, B-Chemical
ketoconazole, B-Chemical
and O
troleandomycin B-Chemical
significantly O
inhibited O
hydroxy O
pravastatin B-Chemical
formation O
by O
human B-Species
liver O
microsomes, O
but O
only O
ketoconazole B-Chemical
inhibited O
3'alpha, B-Chemical
5'beta,6'beta-trihydroxy I-Chemical
pravastatin B-Chemical
formation, O
suggesting O
that O
other O
CYP O
enzymes O
are O
involved O
in O
its O
formation. O
It O
is O
concluded O
that, O
compared O
with O
lovastatin B-Chemical
[CLint B-Chemical
formation O
6'beta-hydroxylovastatin B-Chemical
(microl.min-1.mg-1): O
199 O
+ O
- O
248, O
6'-exomethylene B-Chemical
lovastatin: B-Chemical
138 O
+ O
- O
104)], O
CYP3A-dependent O
metabolism O
of O
pravastatin B-Chemical
[CLint B-Chemical
formation O
3'alpha,5'beta, B-Chemical
6'beta-trihydroxy I-Chemical
pravastatin B-Chemical
(microl.min-1.mg-1): O
0.03 O
+ O
- O
0.03 O
and O
hydroxy O
pravastatin: B-Chemical
0.02 O
+ O
- O
0.02] O
is O
a O
minor O
elimination O
pathway. O
In O
contrast O
to O
lovastatin, B-Chemical
drug O
interactions O
with O
pravastatin B-Chemical
CYP3A-catalyzed O
metabolism O
cannot O
be O
expected O
to O
have O
a O
clinically O
significant O
effect O
on O
its O
pharmacokinetics. O